PSA Nadir After RT+ADT for Prostate Cancer Predicts Outcomes
New findings could have a role in conducting clinical trials of novel systemic therapies.
Diagnosis & Disease Information
Second-Generation Antiandrogens Up Risk for Cognitive, Functional Toxic Effects
The increasing number of indications for second-generation antiandrogens may result in a large group of men at risk for toxic effects, according to investigators.
Real-World mCSPC First-Line Treatment Intensification Remains Low
Study findings highlight the need for earlier mCSPC treatment intensification by urologists and oncologists.
The EMBARK Trial: An Interview With Neal D. Shore, MD
The phase 3 EMBARK trial involved more than 200 global sites and had 8 years of follow-up.
Adding ADT to Radiation Does Not Up Survival in Intermediate-Risk Prostate Cancer
NRG 0815 is a “landmark” study investigating the role of short-term androgen deprivation therapy added to modern, dose-escalated radiation to treat intermediate-risk prostate cancer.
Enzalutamide Ups Metastasis-Free Survival in nmHSPC
Investigators report results from the phase 3 randomized EMBARK trial.
Cardiovascular Disease Risks Persist for Years After Prostate Cancer Diagnosis
Cardiovascular disease is a leading cause of noncancer death in men with prostate cancer.
Study Characterizes Real-World Response to Androgen Inhibitors in mHSPC
PSA response is an important early indicator of progression-free survival in mHSPC.
Adding Androgen Deprivation Therapy to MDT Beneficial in Oligometastatic CSPC
In a study of oligometastatic castration-sensitive prostate cancer, metastasis-directed therapy (MDT) with concurrent ADT vs MDT alone was significantly associated with a greater 5-year rate of freedom from biochemical progression.
Locally Advanced, Low Metastatic Burden Prostate Cancer Have Similar Outcomes
Investigators observed no significant difference in development of castration-resistant prostate cancer and overall mortality.
- Loading...
Loading...
Next post in AUA 2023 Annual Meeting
Loading... 
Loading...